Sustained-release naltrexone may slightly increase illicit opioid use and serious adverse events compared to opioid agonists, with uncertain effects on retention and acceptability. It may reduce ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

All of which is to say that I don't lack for morning energy. I do make a cup of coffee, but it is as much about the process ...

Linerixibat, an investigational oral ileal bile acid transporter (IBAT) inhibitor, improved cholestatic pruritus in patients ...

With a demand that vaccine boosters be tested against placebos, RFK Jr. puts an old antivaccine claim at the forefront of government health policy.

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

The nocebo effect appears to work more strongly and more persistently than the placebo effect when it comes to pain, a new ...

Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with atherosclerotic cardiovascular ...

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

A blanket requirement for placebo-controlled trials threatens research ethics and vaccine access, it’s being argued.

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

Health and Human Services Secretary Robert F. Kennedy Jr. has misleadingly claimed that vaccines are not tested in ...